Moviprep

Polyethylene glycol 3350 with electrolytes and ascorbic acid, the active ingredient in Moviprep, is an osmotic laxative presented as an oral solution for oral use. The formulation combines polyethylene glycol 3350 with potassium chloride, sodium chloride, sodium sulfate and ascorbic acid to create an osmotic gradient that draws water into the intestinal lumen, producing rapid and tolerable bowel evacuation. It is used to cleanse the bowel before colonoscopy or sigmoidoscopy in adult patients.

GNH USA supplies Moviprep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global distribution.

Moviprep, an osmotic laxative, is employed for bowel cleansing in gastrointestinal endoscopic procedures.

Colonoscopy: provides thorough bowel cleansing to enable clear visualization of the colon during the procedure. Sigmoidoscopy: ensures adequate preparation of the distal colon and rectum for optimal examination. Other lower GI endoscopy: facilitates effective bowel evacuation for procedures such as flexible sigmoidoscopy or virtual colonoscopy.

Moviprep may cause a range of adverse reactions, most of which are related to its osmotic activity and electrolyte content.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Abdominal bloating: sensation of fullness or distension. - Abdominal cramping: intermittent painful contractions.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss requiring medical attention. - Significant electrolyte imbalance: marked changes in sodium, potassium or other electrolytes. - Allergic reaction: rash, itching, swelling or anaphylaxis.

Before prescribing Moviprep, clinicians should evaluate patient-specific factors and follow safety measures to minimise risks.

Assess renal function: verify creatinine clearance prior to use. Evaluate electrolyte status: correct existing imbalances before administration. Use with caution in inflammatory bowel disease: risk of symptom exacerbation. Avoid in bowel obstruction or perforation: contraindicated in these conditions. Adjust dose in elderly or debilitated patients: monitor tolerance closely. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Moviprep can interact with other medications that affect fluid and electrolyte balance or gastrointestinal motility.

Major Interactions (Avoid): - Concomitant use with other osmotic laxatives: may cause excessive fluid loss. - Co‑administration with high‑dose diuretics: risk of severe dehydration and electrolyte disturbances. - Simultaneous IV electrolyte replacement solutions: may lead to unpredictable electrolyte shifts.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: may alter bowel preparation efficacy. - NSAIDs: increase risk of gastrointestinal irritation. - Oral rehydration salts: may require adjustment of Moviprep volume.